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AbstrAct
Prostate cancer (PCa) is the most commonly diagnosed neoplasm and the 
second leading cause of cancer-related deaths in men. Acquisition of resistance 
to conventional therapy is a major problem for PCa patient management. Several 
mechanisms have been described to promote therapy resistance in PCa, such as 
androgen receptor (AR) activation, epithelial-to-mesenchymal transition (EMT), 
acquisition of stem cell properties and neuroendocrine transdifferentiation (NEtD). 
Recently, we identified Brachyury as a new biomarker of PCa aggressiveness and 
poor prognosis. In the present study we aimed to assess the role of Brachyury in PCa 
therapy resistance. We showed that Brachyury overexpression in prostate cancer cells 
lines increased resistance to docetaxel and cabazitaxel drugs, whereas Brachyury 
abrogation induced decrease in therapy resistance. Through ChiP-qPCR assays we 
further demonstrated that Brachyury is a direct regulator of AR expression as well 
as of the biomarker AMACR and the mesenchymal markers Snail and Fibronectin. 
Furthermore, in vitro Brachyury was also able to increase EMT and stem properties. 
By in silico analysis, clinically human Brachyury-positive PCa samples were associated 
with biomarkers of PCa aggressiveness and therapy resistance, including PTEN 
loss, and expression of NEtD markers, ERG and Bcl-2. Taken together, our results 
indicate that Brachyury contributes to tumor chemotherapy resistance, constituting 
an attractive target for advanced PCa patients. 
IntroductIon
Prostate cancer (PCa) is the most prevalent 
malignancy in men and the second leading cause of cancer-
related deaths [1]. Despite advances in prevention, early 
detection, surgical techniques and adjuvant radiotherapy/
chemotherapy, progression to advanced prostate cancer 
and metastasis is a frequent event that hinders patient’s 
cure [2]. The fist-line therapy for PCa patients includes 
the blockade of androgen receptor (AR) activation and 
signaling based on androgen-deprivation therapy. This 
approach is effective at an early phase, but eventually 
tumors recur, leading to the known metastatic castration-
resistant prostate cancer (mCRPC) with a lethal outcome 
[3]. The exact mechanisms underlying the development of 
mCRPC are not fully understood. It was proposed that it 
arises when cancer cells either maintain AR signaling in 
the absence of normal levels of ligand or no longer require 
activation of this pathway for survival and proliferation 
[11]. It has also been suggested an association between 
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chemoresistance and epithelial-to-mesenchymal transition 
(EMT) in PCa, a mechanism by which cancer cells acquire 
a higher capacity to invade and further metastasize 
[13], as well as increased stem cell features (e.g. CD15 
and CD133) [14, 15]. Moreover, androgen-deprivation 
therapy frequently induces the emergence of highly 
aggressive prostate phenotypes with neuroendocrine 
(NE) features [expression of chromogranin A (CHGA) 
and synaptophysin (SYP)], also called neuroendocrine 
transdifferentiation (NEtD) [16]. Thus, it is crucial 
to understand these mechanisms in order to identify 
therapeutic biomarkers and potential novel therapeutic 
approaches for these patients. Currently, docetaxel is 
one of the commonest therapeutic agent given as first-
line chemotherapy for patients with mCRPC [4-6]. In the 
mCRPC patients with docetaxel-resistant phenotypes, 
it has been shown the survival benefit with second-line 
therapy using new drugs such as enzalutamide, abiraterone 
and cabazitaxel [7-10]. 
The T-box transcription factor Brachyury (T) plays a 
key role during early embryo gastrulation, a typical EMT 
process [22]. Lately, Brachyury has also been associated 
with tumor development and progression [17-21], and its 
role on EMT, stemness and cancer therapy resistance was 
described [23-29]. 
We recently reported Brachyury as a new and 
independent biomarker of poor prognosis in PCa patients 
[21, 30]. We also demonstrated that Brachyury could 
be involved in EMT, stem and neuronal differentiation 
[21], an indicative of NEtD in PCa. In the present work 
we aimed to explore whether Brachyury is a molecular 
driver of the major mechanisms of prostate tumor therapy-
resistance, namely AR, EMT, NEtD and stemness, 
in prostate cancer cells treated with docetaxel and 
cabazitaxel. 
results
brachyury promotes prostate cancer cell 
resistance to the chemotherapeutic agents 
docetaxel and cabazitaxel 
Comparing only the control cells (transfected with 
empty vectors), the metastatic PC3 cells (with endogenous 
Brachyury expression) demonstrated to be more resistant 
to docetaxel and cabazitaxel than the primary PCa 
22RV1 and the bone metastatic DU145 cells (negative 
for Brachyury expression) (Supplementary Figure S1B). 
To explore the hypothesis that Brachyury could influence 
therapy response, we used the primary PCa 22RV1 
and the brain metastatic PCa DU145 cell lines (both 
Brachyury-negative) previously modulated to overexpress 
Brachyury (pcBrachyury) and the bone metastatic PC3 
cell line (Brachyury-positive) with Brachyury sh-mediated 
depletion (sh.Brachyury) (Supplementary Figure S1A) 
[21]. Cells were treated with different concentrations of 
docetaxel or cabazitaxel to determine the IC50 of each 
cell line (22RV1 and DU145 4T/0 vs pcBrachyury; 
PC3 pLKO.1 vs sh.Brachyury). All cell lines used are 
androgen-independent to better explore the implication of 
Brachyury in castrate resistance prostate cancer (CRPC) 
therapy. The overexpression of Brachyury in 22RV1 cells 
was significantly associated with a higher resistance to 
both cytotoxic drugs [(docetaxel: 4/T0 IC50=0.17±0.04nM, 
pcBrachyury IC50=1.54±0.07nM; p<0.001), Figure 1A; 
(cabazitaxel: 4/T0 IC50=1.95±0.06nM, pcBrachyury 
IC50=28.85±1.12nM; p<0.001); Figure 1B]. Similar results 
were also obtained in the metastatic DU145 cell line 
with Brachyury overexpression (Supplementary Figure 
S1C). When Brachyury was depleted on PC3 cells we 
observed a significant decrease in the IC50 for both drugs 
used, compared with control cells [(docetaxel: pLKO.1 
IC50=1.57±0.04nM, sh.Brachyury IC50=0.96±0.03nM; 
p<0.01), Figure 1C; (cabazitaxel: pLKO.1 
IC50=13.37±0.58nM, sh.Brachyury IC50=1.09±0.41nM 
; p<0.05), Figure 1D]. Altogether, these results indicate 
that the presence of Brachyury in PCa cells is directly 
associated with resistance to current chemotherapy-
mediated treatments used in CRPC therapy.
Presence of brachyury in Pca correlates with 
resistance plasticity mechanisms eMt and 
stemness
We have previously shown by in silico analysis in 
PCa samples that Brachyury is associated with altered 
expression of genes involved in epithelial-to-mesenchymal 
transition (EMT), namely E and N-cadherin, Snail, 
TGF-β1, fibronectin, MMP14 and MMP24, and in 
stemness (CD44) [21]. To corroborate our previous 
results, we performed RT-qPCR in a primary PCa cell 
line (22RV1) with modulated Brachyury expression 
(Supplementary Figure S2A). We found that Brachyury 
overexpression was significantly associated with the 
decrease of the epithelial marker E-cadherin and an 
increased expression of the mesenchymal marker Snail 
(Supplementary Figure S2A). 
We further evaluated the involvement of Brachyury 
in gain of stemness properties in PCa cells. We found 
that Brachyury is able to increase the number of prostate-
spheres and the self-renewal capacity over time in 22RV1 
cells Brachyury-positive cells (pcBrachyury) compared 
with Brachyury-negative cells (4/T0) (Figure 2A) (Figure 
2A). Moreover, Brachyury was able to significantly 
increase the expression of the stem markers CD44 and 
CD15 (Figure 2B). Interestingly, we observed that 22RV1 
PCa cells under sphere-forming conditions showed 
an increase of Brachyury expression, when compared 
with cells cultured in basal/monolayer conditions, with 
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statistical significance in endogenous negative cells (4/T0) 
(Figure 2C). The influence of Brachyury in stemness was 
also addressed in metastatic DU145 cell line with ectopic 
Brachyury expression and in PC3 cell line with Brachyury 
depletion. Although we have found an increased number 
of aggregates in Brachyury-positive cells, they not form 
spheres (Supplementary Figure S2B). 
Together, Brachyury overexpression occurring 
in PCa tissues could contribute to tumor cell plasticity 
mechanisms as EMT and gain of stem cell properties. 
Moreover, we showed that prostate tumor cells could up-
regulate Brachyury under stemness conditions.
brachyury is co-expressed with Ar, erG, bcl-
2, netd markers and inversely with Pten in 
human Pca tissues
To assess whether Brachyury is related with AR 
expression, we analyzed 155 normal prostate tissues and 
311 primary PCa tissues by immunohistochemistry (Figure 
3A and 3B), previously characterized for Brachyury 
expression [21]. We found that presence of Brachyury 
protein in the nucleus of primary PCa tissues is statistically 
associated with the presence of AR (p=0.017; Figure 3B), 
a feature not observed in normal prostate tissues (p=0.362; 
Figure 3B). Moreover, western blot analyses of PCa cell 
lines with Brachyury modulation showed that Brachyury 
Figure 1: brachyury promotes resistance to the cytotoxic drugs docetaxel and cabazitaxel. Brachyury overexpression 
increases significantly the IC50 of 22RV1 cells for both A. docetaxel and b. cabazitaxel. Brachyury depletion on PC3 cells decreases the 
IC50 for c. docetaxel and d. cabazitaxel. Data for drug assays are mean ± S.E.M, of 3 biological independent experiments with 3 technical 
replicates each. 
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overexpression significantly increases AR expression 
and when Brachyury is depleted there is a concomitant 
decrease of AR expression (Figure 3C, D, E, F). We also 
observed that docetaxel treatment is able to decrease AR 
expression in 22RV1 cells in absence of Brachyury (4/T0 
22RV1, p<0.05), but not in the Brachyury-overexpressing 
cells. No effect was observed in PC3 cell line, indicating 
that effect of docetaxel in AR downregulation is cell-type 
dependent (Figure 3C, D, E, F). Based on these results, we 
may hypothesize that increased AR expression promoted 
by Brachyury can lead to docetaxel and cabazitaxel 
resistance (Figure 1). 
The correlation between Brachyury and AR was 
also corroborated by in silico analysis in a series of 28 
non-tumoral and 94 PCa samples (Figure 3G). We found 
that expression of the AR was significantly increased in 
PCa tissues as compared to the normal prostate gland 
and is co-expressed with Brachyury (T) (Figure 3A). We 
extended our in silico analysis to other genes described to 
be associated with poor patient prognosis and with PCa 
progression to a castration-resistant phenotype [31, 32]. 
Brachyury co-expression was correlated with PTEN (the 
most frequently downregulated tumor-suppressor gene in 
PCa), Bcl-2 (associated with therapy resistance) and ERG 
Figure 2: brachyury promotes stem cell properties in Pca cells and is re-expressed under pressure conditions. A. In 
22RV1 cells Brachyury is able to enhance the capacity to form prostate-spheres and self-renewal over time, as well as b. increases the 
expression of stem cell markers CD44 and CD15. c. Brachyury is up-regulated in negative 22RV1 cells when cultured under stem cell 
medium. Results of prostate-sphere are representative of two biological independent experiments in duplicate. Graphs of expression are 
mean ± S.E.M of 3 biological independent experiments with 3 technical replicates each. *, p < 0.05.
Oncotarget28895www.impactjournals.com/oncotarget
(overexpressed due TMPRSS2-ERG fusion). As shown 
in Figure 3G, a strong association was found between 
Brachyury expression and Bcl-2 and ERG expression and 
PTEN loss (Figure 3G). 
We previously showed that genes co-expressed 
with Brachyury are clustered in processes of neuron 
differentiation and central nervous system development 
[21]. This finding is indicative that Brachyury could 
be involved in the NEtD process. To better understand 
this mechanism we investigated the co-expression 
Figure 3: brachyury is associated with Ar, bcl-2, erG, cHGA and sYP expression and with loss of Pten expression. 
A. Representative images of Brachyury and AR staining in normal and primary PCa tissues. b. Correlation of Brachyury and AR staining 
in prostate tissues. Nuclear Brachyury staining is correlated with AR only in primary PCa tissues. c.-F. Western blot analyses for Brachyury 
and AR expression in prostate cell lines treated with docetaxel (Doc) or with cabazitaxel (Cab). Graphs represent the densimetric semi-
quantification of western blot images. G. Heatmap showing the co-expression of Brachyruy (T), AR, PTEN, Bcl-2, ERG, CHGA and SYP 
in normal and PCa human samples from Oncomine database. 
Oncotarget28896www.impactjournals.com/oncotarget
of Brachyury with chromogranin A (CHGA) and 
synaptophysin (SYP) in silico, two NEtD markers 
described to distinguish prostate tumors with NE features. 
We found that Brachyury is strongly correlated with NEtD 
markers, reinforcing its involvement in NEtD (Figure 3G). 
A gene signature that includes expression of Brachyury, 
CHGA, SYP, AR and loss of PTEN was found (Figure 
3G), being correlated with more aggressive tumors. The 
direct involvement of Brachyury in CHGA, SYP, AR, Bcl2, 
ERG and PTEN expression is still unclear; however, the 
association with these well-established markers of PCa 
progression supports the importance of Brachyury as a 
new biomarker of PCa aggressiveness.
brachyury directly binds to the promoters of 
snail and Fibronectin (mesenchymal biomarkers), 
AMAcr (Pca biomarker) and Ar 
A correlation between the expression of Brachyury 
with CD44, N-cadherin, Snail, fibronectin, AMACR and 
AR (present study and [21]) in PCa cells suggested that 
Brachyury could directly regulate these genes. To validate 
this hypothesis, we performed ChIP-qPCR in PC3 cell 
line with endogenous Brachyury expression. Analyses 
of 6Kbs (-5Kb to +1Kb) of the CD44, N-cadherin, Snail, 
Fibronectin, AMACR and AR promoter regions revealed 
presence of T-Box binding sites in all genes (Figure 4A, 
T-Boxs represented in red). However, a higher number 
T-Box binding site clusters was only found on AR 
(26 T-Boxs), AMACR (25 T-Boxs), Snail (11 T-Boxs) 
and Fibronectin (9 T-Boxs) in opposite with CD44 
and N-cadherin that only present 2 and 3 T-Box sites, 
respectively (Figure 4A). 
The cross-linked DNA-protein complexes were 
immunoprecipitated with anti-Brachyury or with control 
IgG antibody. PCR amplification was performed using 
primers flanking regions with T-Boxs (blue arrows, 
Figure 4A). The results of ChIP-qPCR analysis showed 
that upstream regions of the mesenchymal marker genes 
Snail and Fibronectin, the PCa biomarker AMACR and AR 
precipitated with anti-Brachyury antibody showing that 
Brachyury directly binds to regulatory elements of these 
genes and suggests possibly regulation of those genes 
(Figure 4B).
dIscussIon
In the present study we provided the first evidences 
that Brachyury regulates several biological mechanisms 
associated with of PCa therapy resistance. Importantly, we 
showed that Brachyury directly regulates AR expression 
and promotes chemoresistance in PCa cells. Moreover, 
we also showed that Brachyury might also be a direct 
regulator of AMACR biomarker, in agreement with 
Figure 4: brachyury directly binds to the promoter regions of snail, Fibronectin, AMAcr and Ar. A. Squematic 
representation of the T-Boxs (red) in the region analyzed (6Kbs) and the localization of the primers (blue arrows) used in the ChIP-qPCR. 
b. Brachyury showed an enrichment of chromatin immunoprecipitated for Snail, Fibronectin, AMACR and AR, but not for the negative 
control β-actin, CD44 and N-cadherin. The graph represents mean ± S.E.M. of three biological experiments with 3 technical replicates.
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our previously results [21]. These results indicate that 
Brachyury alone or in combination with AMACR, could 
be used in routine setting as a PCa diagnosis biomarker.
Using ChiP-qPCR we were able to show that 
Brachyury is a direct regulator of AR. This finding 
was further validated by immunohistochemistry of a 
cohort of PCa patients and in silico analysis. We found 
a particular association when Brachyury is present 
only in the nucleus, not in the cytosol. We believe that 
correlation of Brachyury and AR in the nucleus could be 
a direct consequence of Brachyury role in activation AR 
expression and consequently therapy resistance. Moreover, 
Brachyury presence in the cytosol could be a surrogate 
marker of PCa aggressiveness. By ChiP-qPCR, we also 
observed that Snail and Fibronectin - typical mesenchymal 
markers - are directly regulated by Brachyury, strongly 
suggesting its role in the EMT process. These results 
are in agreement with our previous study, where we 
showed that Brachyury increases migration and invasion 
capabilities in PCa cells and it was correlated with EMT 
markers (fibronectin, MMP14, MMP24, Snail, IL8 and 
TGF-β1) by in silico analysis [21]. Moreover, Brachyury 
overexpression increases expression of stem cell markers 
(CD44, CD15 and Nestin) being associated with increased 
capacity of PCa cells to form prostate-spheres and with 
self-renewal in 22RV1 cell line. The absence of effect on 
stem in the other PCa cell lines suggests that Brachyury 
is not the only mechanism responsible for increased stem 
cell capabilities, but probably it involve more complex 
mechanisms, once the genetic background of each cell 
line could influence it. Furthermore, Brachyury was also 
associated with NE markers (CHGA and SYP), reinforcing 
the hypothesis that it is involved in the NEtD process and 
consequently higher aggressive tumors. Brachyury was 
previously associated with the NE marker CHGA, in 
colorectal cancer, distinguishing a specific subpopulation 
of stem cells [33]. 
The involvement of Brachyury in tumor resistance, 
namely to docetaxel, was previously described in 
breast cancer [27, 28]. In accordance, we demonstrated 
that Brachyury promotes higher resistance not only 
to docetaxel, but also to cabazitaxel, two currently 
chemotherapeutic agents used in CRPC treatment. A 
recent genome-wide analysis on AR that showed an 
enrichment of T-Box motifs in LAPC-4 prostate cells after 
chemotherapy [34], indicating that Brachyury is involved 
in AR expression during PCa therapy and consequently 
increased therapy resistance. We hypothesize that this 
effect on Brachyury expression can be extrapolated to 
other pressure conditions, as longer periods exposed to 
chemotherapy. Interestingly, we found that Brachyury can 
be re-expressed under pressure conditions, as can happen 
during chemotherapy of PCa. Indeed, lung cancer cells 
exposed to successive cycles of chemotherapy (docetaxel) 
selection and recovery showed elevated Brachyury 
expression levels compared with untreated cells [18]. 
Several molecular events, such as TMPRSS2-ERG 
fusion, Bcl-2 overexpression, as well as PTEN loss has 
been described as major biomarkers of PCa aggressiveness 
and therapy response [35-38]. Herein, we showed that 
Brachyury is co-expressed with the ETS transcription 
factor ERG, Bcl-2 and inversely co-expressed with PTEN. 
In hepatocellular carcinoma cells, Brachyury showed to 
increase Akt signaling activation by inhibition of PTEN 
expression [39]. This recent finding together with the 
present data, suggest that in PCa Brachyury can suppress 
PTEN leading to increased activation of Akt signaling 
and consequently aberrant transcription of down-
stream checkpoint genes, like Bcl-2 and ERG. Aberrant 
expression of an ETS transcription factor (usually ERG) 
is also found in response to the activated AR [38], as those 
promoted by Brachyury overexpression. This signaling 
crosstalk could provide the selective advantage at the 
cellular level to allow PCa progress and be resistant to 
current therapy. Therefore, Brachyury can constitute an 
attractive therapeutic target.
Recently a Phase II clinical trial was initiated with 
the yeast-Brachyury vaccine GI-6301 (www.clinicaltrials.
gov, NCT02383498, 2015) to treat patients with advanced 
carcinomas. Preliminary results showed that Brachyury 
vaccine was well tolerated and Brachyury-specific 
CD8+ and/or CD4+ T-cell responses were present in the 
blood of some patients post- versus pre-vaccination [40, 
41]. This evidence together with results obtained in the 
present study indicates that Brachyury could be used as an 
immunotherapeutic target in patients with advanced PCa.
In conclusion, we have demonstrated the importance 
of Brachyury in PCa resistance to chemotherapeutic 
agents by modulating several tumorigenic and aggressive 
mechanisms. Additionally the previous association of 
Brachyury with PCa patient prognosis [21] and current 
therapy response suggest that Brachyury could be a 
important theranostic biomarker for advanced prostate 
cancer patients. 
MAterIAls And MetHods
brachyury and androgen receptor (Ar) 
correlation in human prostate tissues
AR and Brachyury co-expression was assessed in a 
cohort of 155 normal prostate tissues and 311 primary PCa 
tissues, where we previously described the expression and 
distribution of Brachyury [21]. 
For AR staining histological slides with 4 μm-thick 
tissue sections were subjected to immunohistochemistry 
analysis according to the streptavidin-biotin peroxidase 
complex system (UltraVision Large Volume Detection 
System Anti-Polyvalent, HRP; LabVision Corporation), 
using the primary antibody raised against AR (diluted 
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1:750; sc-816, Santa Cruz Biotechnology, Inc). AR 
immunohistochemistry results were semi-quantitatively 
scored. Tumors were graded as negative when expression 
was seen in less than 5% of nuclei, 1 when staining 5% 
to 10% of nuclei, 2 when staining more than 10% to 50% 
of nuclei, and 3 when staining more than 50% of nuclei. 
Samples with scores 0, 1 were considered negative and 
those with scores 2 and 3 were considered positive.
cell lines and cell culture conditions
Human prostate cell lines 22RV1, DU145 and PC3 
(ATCC-American Type Culture Collection, MD, USA) 
were grown in Roswell Park Memorial Institute medium 
(RPMI)-1640 (GIBCO®, Invitrogen) cell culture medium 
supplemented with 10% Fetal Bovine Serum (FBS) 
(GIBCO®, Invitrogen) and 1% Penicillin-Streptomycin 
(P/S) (GIBCO®, Invitrogen). 
brachyury over-expression and silencing in Pca 
cells
22RV1 and DU145 were transfected with full-
length human Brachyury cDNA in pcDNA4/T0 vector 
(designed as pcBrachyury) or with empty vector (4/T0). 
For Brachyury silencing, PC3 cells were transfected with 
pLKO.1 plasmid containing Brachyury-specific shRNA 
(sh.Brachyury) or empty vector alone (pLKO.1) [21]. 
Transfected 22RV1 and DU145 cells were maintained 
under selection with Zeocin 50μg/ml (Invitrogen). Stable 
PC3 cells with depleted endogenous Brachyury expression 
were maintained with 5μg/ml of puromycin (Sigma 
Aldrich), as previously described [21].
Western blot analysis
Cells were lysed in 50 mM Tris pH 7.6-8, 150 
mM NaCl, 5 mM EDTA, 1 mM Na3VO4, 10 mM NaF, 
10 mM NaPyrophosphate, 1% NP-40 and 1/7 of protease 
cocktail inhibitors (Roche). Proteins were resolved 
on standard 12% SDS-PAGE gel and transferred onto 
nitrocellulose membranes. The immunodetection was 
achieved using antibodies for human Brachyury (AF2085, 
R&D Systems), AR (ab108341, Abcam) and β-actin 
(sc-1616, Santa Cruz Biotechnology). Detection was 
done by chemiluminescence (SuperSignal West Femto 
Chemiluminescent Substrate; Thermo Scientific). Protein 
expression quantification was performed by ImageJ 
software (version 1.44).
rnA extraction and reverse-transcriptase (rt) 
cdnA synthesis
Total RNA was extracted from cell lines using 
TRIzol® Reagent (Invitrogen). The concentration and 
purity of RNA was evaluated by spectrophotometry 
(Nanodrop Technologies, Inc). One µg of RNA was used 
for cDNA synthesis, using the High-Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems), as 
recommended by the manufacturer. 
Quantitative polymerase chain reaction (qPcr)
qPCR was performed in a CFX96 detection system 
(BioRad), using SSOfast Evagreen supermix (BioRad) 
following the manufacturer’s instructions. Optimized 
cycling conditions for qPCR was as follows: enzyme 
activation for 30 seconds at 95ºC; 45 cycles of denaturation 
at 95ºC for 5 seconds and annealing/extension at 59ºC for 
5 seconds. Melting curve was assessed at 65ºC - 95ºC (in 
0.5ºC increase) at each 5 seconds/step. The primers used 
are presented in Supplementary Table 1. The expression 
levels were normalized to β-actin by ΔCT (relative 
expression) or by ΔΔCT method (fold-change). Results are 
presented as the mean ± SD of 3 independent experiences 
in triplicate.
t- box binding sites and primer design
A total of 6Kbs (-5KB to +1Kb) for CD44, Snail, 
Fibronectin, N-cadherin, AMACR and AR were screened 
for T-Box binding consensus sequences (Supplementary 
Figure S3A). β-actin was used as negative control of 
Brachyury binding (data from ChIP-sequencing in human 
chordoma cells) [42]. To look for T-Box binding sites we 
used JASPAR database (http://jaspar.genereg.net) that 
contains a matrix-based nucleotide profile of binding 
preference for transcription factors from multiple species. 
Primers (Supplementary Table 1) were designed flanking 
regions enriched in T-Box binding sites.
chromatin immunoprecipitation (chIP) - qPcr
ChIP-qPCR analysis was performed in PC3 cell 
line containing Brachyury endogenous expression. The 
protocol used was adapted from [42]. Briefly, adherent 
PC3 cells (∼3×107) were fixed for 5 minutes in situ with 
1.27% formaldehyde solution (Sigma F8775). Immediate 
quenching of formaldehyde with glycine 2.5M (1/20 of 
total volume) was performed for 5 minutes. Cells were 
washed twice with 1× Dulbecco’s phosphate buffered 
saline (PBS 1X), harvested using a cell scraper (Sarstedt, 
NC, USA), centrifuged and the pellet cells were quickly 
washed with ice-cold PBS 1X. PBS was totally removed 
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and pellets were snap-frozen in liquid nitrogen and stored 
at −80°C.
Pellets were homogenized with cell lysis buffer 
(10mM Tris-HCl pH=7.5, 10mM NaCl, 0.5% NP-40) and 
left on ice for 1-2 hours. After centrifugation, supernatant 
pellet was re-suspended in nuclei lysis buffer (50mM 
Tris-HCl pH=7.5, 10mM EDTA pH=8.0, 1% SDS) and 
kept on ice for 15-30 minutes. At this stage, 2X volumes 
of IP dilution buffer (16.7mM Tris-HCl pH=7.5, 167mM 
NaCl, 1.2mM EDTA pH=8.0, 0.01% SDS) was added 
to each pellet of cells. Chromatin was solubilized and 
sheared to fragments of 100-500bp peaking around 200bp 
(Supplementary Figure S3B) using an ultrasonic processor 
(Vibra-cell sonicator; Sonics and Materials, INC) (10 
cycles of 30 seconds shock waves at 3 Watt interrupted by 
30 seconds pauses). 
Magnetic Dynabeads Protein G (Novex, Life 
Technologies) were blocked in PBS containing 0.5% (w/v) 
BSA and coupled to ChIP-grade antibody (or control rabbit 
IgG) at 4ºC overnight. 6μg of Brachyury antibody (sc-
20109, Santa Cruz Biotechnology) was coupled to 50μl of 
the appropriate Dynabeads Protein G. The soluble nuclear 
extract was prepared for immunoprecipitation by adding 
80μl of 10% Triton X-100 per 1ml of chromatin. A sample 
of 50μl of ChIP input was collected at this stage and 
stored at 4ºC. Then the nuclear extract was combined with 
antibody-coupled beads (Brachyury or control IgG) and 
incubated at 4ºC overnight with rotation. After incubation, 
magnetic beads were precipitated using an eppendorf-
magnet and washed with pre-chilled RIPA buffer (50mM 
HEPES pH=7.6, 500mM LiCl, 1mM EDTA, 1% NP-40, 
0.7% (w/v) Na-deoxycholate). Bound chromatin was 
eluted from the beads with elution buffer (50mM Tris-HCl 
pH=8.0, 10mM EDTA pH=8.0, 1% SDS) and reversed 
cross-linked in a thermomixer (65ºC, 6-hours). After 
reverse cross-link, 1 volume of TE pH=8.0 and 200μg/
ml of RNase A (Invitrogen) was added to the samples for 
a 1-hour incubation at 37ºC. The samples were further 
treated with 200μg/ml of proteinase K (Ambion) for 
1-hour at 55ºC. Finally, the DNA fragments were purified 
with phenol:chloroform:isoamylalcohol (phenol:Chl:1A, 
Sigma) and precipitated in 1/20 volume of 5M NaCl, 20μg 
of glycogen and ethanol. ChIP-chromatin was diluted in 
30μl of DNase-free water. 
DNA enrichment was quantified in real-time PCR 
relative to locus-specific standard curves using CFX96TM 
system (BioRad). The percentage of DNA enrichment 
for a specific antibody was normalized to the amount 
of total DNA (equivalent to Input DNA): (Ab-IgG)/
Input. Real-time PCR was carried out with the following 
conditions: 30 seconds at 95ºC, 5 seconds at 59ºC and 
72ºC respectively, 60 cycles. qPCR runs were performed 
with 3 technical replicates.
Prostate-sphere assay
Prostate sphere assay (adapted from [43]) was 
used to evaluate the capacity of prostate cells to grow 
and form spheres in suspension, an indicative of higher 
stemness phenotype. Each sample of cells was counted 
(1x103cells/well), resuspended in 2mL of Neurobasal 
media (Invitrogen, Carlsbad, CA), supplemented with 
2 mM glutamine and B27 (Invitrogen) and plated on 
a 12-well plate. Spheres were counted 3-15 days after 
plating. For passaging of spheres, media was collected 
centrifuged at 900rpm for 5 minutes to pellet the spheres. 
The supernatant was then removed and spheres were 
mechanically dissociated in 1mL of fresh medium to 
obtain single cell suspension. Cells were counted and 
re-plated at a density of 1x103cells/well to evaluate the 
capacity of self-renewal.
drug treatment and determination of half-
maximal inhibitory concentration (Ic50) 
The conventional and metastatic-second line 
PCa cytotoxic drugs docetaxel and cabazitaxel 
(MedChemTronica), respectively, were used to study the 
therapeutic value of Brachyury on PCa cells. Drugs were 
diluted in dimethyl sulfoxide (DMSO), as recommended 
by the manufacture. To determine the IC50 of the drugs 
4x103 cells/well for 22RV1 and 2X103 cells/well for PC3 
were plated into 96-well plates in triplicate and allowed 
to adhere overnight. After 6-hours of starvation (RPMI 
only) cells were treated with different concentrations 
of docetaxel (0, 0.5, 2, 5, 10, 100 and 1000nM) or 
cabazitaxel (0, 0.1, 0.5, 5, 10, 500 and 1000nM) in culture 
medium supplemented with 10% FBS. After 48-hours 
of drug incubation the cellular viability was assessed by 
MTS (Promega, USA) in a 10:1 ratio and incubated in a 
humidified atmosphere at 37 ºC and 5% CO2. Following 
2 hours of incubation the optical density was determined 
at 490nm in the Varioscan-Flash plate reader (Thermo 
Scientific). The cells treated with vehicle were incubated 
with culture medium containing 10% FBS and 1% DMSO. 
To assess AR and Brachyury protein expression after drug 
treatment cells were cultured (3x105 cells/well) in a 6-well 
plate and allowed to adhere over-night. In the next day 
cells were treated with docetaxel or cabazitaxel (lowest 
IC50 for each cell line was used) for 24 hours. Controls 
were treated with 1% DMSO. Cells were then collected 
for protein extraction and western blot analyses.
In silico microarray expression analysis 
Analysis of co-expression of Brachyury, AR, PTEN, 
ERG, Bcl-2 and genes involved in NEtD (SYP and CHGA) 
was performed using data extracted from Oncomine 
Oncotarget28900www.impactjournals.com/oncotarget
database [44, 45]. For this study we used the Grasso 
dataset [46] compromising 28 normal prostate glands and 
94 PCa tissues, the only dataset with the information for 
the 7 genes of interest.
statistical analysis
Correlations between Brachyury and AR expression 
in human samples were performed using the chi-square 
test (χ2-test). Simple comparisons between two different 
conditions were analyzed using Student’s t test. The 
statistical analysis was performed using SPSS software 
(version 19.0) or using Prism GraphPad software (version 
5.0a). The level of significance in the statistical analyses is 
indicated as *=p<0.05, **=p<0.01 or ***=p<0.001.
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